CAMBRIDGE, Mass.– Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery technology, ARMMs, today announced the appointment of Paulash Mohsen as Chief Executive Officer.
“Paulash joins Vesigen with a broad range of skills, experience and accomplishments that are an excellent fit to lead an emerging innovation-focused biotechnology company such as Vesigen,” said Gerald Chan, Sc.D., Chairman of Vesigen’s Board of Directors. “His experience at both large pharma and small biotech companies will be invaluable as we continue advancing our novel programs. On behalf of our Board and management team, we welcome Paulash and look forward to his executive leadership.”
Mr. Mohsen is a seasoned biopharmaceutical executive who has served in a variety of roles across multiple disciplines. Prior to his appointment at Vesigen, he served as Chief Business Officer at Yumanity Therapeutics, and helped the company grow from a seed stage, research-based startup to a public company, with a lead clinical program in Parkinson’s disease. He was responsible for securing a strategic research collaboration and license agreement with Merck & Co. for two pipeline programs in amyotrophic lateral sclerosis and frontotemporal lobar dementia. Before Yumanity, Mr. Mohsen served as Country Manager in Canada for Cubist Pharmaceuticals (acquired by Merck), where he led the company’s first international operation from conceptualization through commercialization. In this role, he oversaw the approval and launch of two novel anti-infective therapeutics and led the company’s commercial, scientific and administrative functions. Mr. Mohsen joined Cubist via acquisition of Optimer Pharmaceuticals, where he was Vice President, Strategy and Business Operations and helped establish the U.S. commercial infrastructure and led launch preparedness for DIFICID, an anti-infective. Preceding Optimer, Mr. Mohsen held strategic and operational roles at Pfizer, including Vice President of Strategy and Vice President, Multi-Channel Management. Mr. Mohsen holds a B.S. in Chemical Engineering from Brown University, an M.S. in Chemical Engineering from the Massachusetts Institute of Technology and an MBA from Harvard Business School.
Vesigen is a biotechnology company developing drugs based on its patented ARRDC1-mediated microvesicles (ARMMs) technology, a class of fusogenic extracellular vesicles produced by cells to package and deliver communication signals between cells and tissues. Currently, a wide range of therapeutic agents, including RNAs, proteins, and gene-editing complexes have been packaged into ARMMs and functionally delivered intracellularly in vitro and in vivo.
“What attracted me to Vesigen was both its innovative platform and the experience and ingenuity of its management team and research staff,” said Mr. Mohsen. “I am excited to begin working with this world-class team to break through delivery barriers and enable the next generation of therapeutics for patients worldwide.”
